Incyte

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Incyte
MorphoSys
lymphoma
tafasitamab
Flag link:
Incyte stock slammed after study fails to hit goal
Incyte stock slammed after study fails to hit goal
Marketwatch
Incyte
clinical trials
itacitinib
graft vs host disease
Flag link:
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Incyte
Jakafi
innovation
Flag link:
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Flag link:
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
BioSpace
earnings
Pfizer
Merck
Amgen
Incyte
JNJ
Flag link:
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Yahoo/Zacks.com
Incyte
earnings
Flag link:
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Endpoints
Incyte
FDA
graft vs host disease
Jakafi
Flag link:
3 Drug Stocks Poised for Gains After Cancer Conference
3 Drug Stocks Poised for Gains After Cancer Conference
Investopedia
ESMO
cancer
Amgen
Incyte
Bristol-Myers Squibb
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo
Pharmaceutical Business Review
Incyte
clinical trials
ruxolitinib
vitiligo
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
This Could Be a Big Year for Incyte
This Could Be a Big Year for Incyte
Motley Fool
Incyte
Jakafi
blood cancers
Flag link:
Novartis’ lung cancer drug edges closer to market after FDA grants fast review
Novartis’ lung cancer drug edges closer to market after FDA grants fast review
Pharmaforum
Novartis
Incyte
FDA
breakthrough therapy
non-small cell lung cancer
Flag link:
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
BioCentury
Zai Lab
China
PD-1 inhibitors
Incyte
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Yahoo/Zacks.com
FDA
Incyte
Jakafi
graft vs host disease
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
Flag link:
Biotech Companies Provide High Median Salaries, Analysis Shows
Biotech Companies Provide High Median Salaries, Analysis Shows
BioSpace
salaries
biotech
Incyte
Celgene
Vertex Pharmaceuticals
Flag link:

Pages